Pan-cancer analysis reveals TAp63-regulated oncogenic lncRNAs that promote cancer progression through AKT activation

Marco Napoli, Xiaobo Li, Hayley D. Ackerman, Avani A. Deshpande, Ivan Barannikov, Marlese A. Pisegna, Isabelle Bedrosian, Jürgen Mitsch, Philip Quinlan, Alastair Thompson, Kimal Rajapakshe, Cristian Coarfa, Preethi H. Gunaratne, Douglas C. Marchion, Anthony M. Magliocco, Kenneth Y. Tsai and Elsa R. Flores ()
Additional contact information
Marco Napoli: H. Lee Moffitt Cancer Center and Research Institute
Xiaobo Li: H. Lee Moffitt Cancer Center and Research Institute
Hayley D. Ackerman: H. Lee Moffitt Cancer Center and Research Institute
Avani A. Deshpande: H. Lee Moffitt Cancer Center and Research Institute
Ivan Barannikov: H. Lee Moffitt Cancer Center and Research Institute
Marlese A. Pisegna: H. Lee Moffitt Cancer Center and Research Institute
Isabelle Bedrosian: The University of Texas M.D. Anderson Cancer Center
Jürgen Mitsch: Advanced Data Analysis Centre
Philip Quinlan: Advanced Data Analysis Centre
Alastair Thompson: Baylor College of Medicine
Kimal Rajapakshe: Baylor College of Medicine
Cristian Coarfa: Baylor College of Medicine
Preethi H. Gunaratne: University of Houston
Douglas C. Marchion: H. Lee Moffitt Cancer Center and Research Institute
Anthony M. Magliocco: H. Lee Moffitt Cancer Center and Research Institute
Kenneth Y. Tsai: H. Lee Moffitt Cancer Center and Research Institute
Elsa R. Flores: H. Lee Moffitt Cancer Center and Research Institute

Nature Communications, 2020, vol. 11, issue 1, 1-16

Abstract: Abstract The most frequent genetic alterations across multiple human cancers are mutations in TP53 and the activation of the PI3K/AKT pathway, two events crucial for cancer progression. Mutations in TP53 lead to the inhibition of the tumour and metastasis suppressor TAp63, a p53 family member. By performing a mouse-human cross species analysis between the TAp63 metastatic mammary adenocarcinoma mouse model and models of human breast cancer progression, we identified two TAp63-regulated oncogenic lncRNAs, TROLL-2 and TROLL-3. Further, using a pan-cancer analysis of human cancers and multiple mouse models of tumour progression, we revealed that these two lncRNAs induce the activation of AKT to promote cancer progression by regulating the nuclear to cytoplasmic translocation of their effector, WDR26, via the shuttling protein NOLC1. Our data provide preclinical rationale for the implementation of these lncRNAs and WDR26 as therapeutic targets for the treatment of human tumours dependent upon mutant TP53 and/or the PI3K/AKT pathway.

Date: 2020
References: Add references at CitEc
Citations:

Downloads: (external link)
https://www.nature.com/articles/s41467-020-18973-w Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:natcom:v:11:y:2020:i:1:d:10.1038_s41467-020-18973-w

Ordering information: This journal article can be ordered from
https://www.nature.com/ncomms/

DOI: 10.1038/s41467-020-18973-w

Access Statistics for this article

Nature Communications is currently edited by Nathalie Le Bot, Enda Bergin and Fiona Gillespie

More articles in Nature Communications from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().